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Keratins are the major structural proteins of the epi­
dermis. Analyzing keratin gene sequences, appreciat­
ing the switch in keratin gene expression that takes 
place as epidermal cells commit to terminally differ­
entiate, and elucidating how keratins assemble into 10-
nm filaments have provided the foundation that has 
led to the discoveries of the genetic bases of two major 
classes of human skin diseases. In this report, we review 
EPIDERMAL DIFFERENTIATION AND THE SWITCH 
IN KERATIN EXPRESSION 
At the interface between the traumas of the environment and the 
body, the epidermis serves a protective function [1 ]. It manifests this 
role by constructing an extensive cytoskeletal architecture of 10-nm 
keratin filaments. Basal epidermal cells display a network of rela­
tively dispersed keratin filaments, composed of the type II keratin 
KS and the type I keratin K14 [2,3]. As basal cells cease to divide and 
begin their journey to the skin surface, they switch from expressing 
the KS and K14 genes to K1 (type II) and K10 (type I) [4,S]. Asso­
ciated with this switch is a morphologic change: K1/K10 filaments 
in suprabasal cells aggregate to form tonofibrillar bundles that are 
thicker than KS/K14 tonofilament bundles in basal cells. This in­
crease in filament bundling may enhance the ability of keratins to 
survive the ensuing destructive phase, when flattened squames are 
produced, leaving 8S% of the terminally differentiated keratino­
cytes as keratin. 
KERATIN FILAMENT ASSEMBLY AND STRUCTURE 
The structure of the 10-nm keratin filament has provided insights as 
to how keratins impart their protective function to the epidermis. 
Keratins belong to the superfamily of intermediate filament (IF) 
proteins, which in vitro can self-assemble into 10-nm cytoskeletal or 
nuclear matrix fibers (for review, see [6,7]). The typifying feature of 
cytoskeletal IF polypeptides is a central, 310 amino acid a-helical 
coil, referred to as the rod containing heptad repeats of hydrophobic 
residues that enable them to intertwine along a hydrophobic seal 
with a second IF protein. Interspersed by three short non-helical 
linker regions, the rod is subdivided into four segments, referred to 
as helix lA, IB, 2A, and 2B. The rod domains of type I and type II 
keratins form parallel, unstaggered, coiled-coil heterodimers, two 
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the cell biology and human genetics of these diseases, 
epidermolysis bullosa simplex and epidermolytic hy­
perkeratosis. Both of these diseases are epidermal dis­
orders of keratin, typified by cell fragility as a conse­
quence of defects in the mechanical strength of basal 
epidermolysis bullosa simplex or suprabasal epider­
molytic hyperkeratosis cells.] Invest Dermatol103:25S-
30S,1994 
of which then align in antiparallel fashion to form stable heterote­
tramers ([6] and references therein). More than SOOO heterote­
tramers then interact in a complex hierarchy of lateral and end-to­
end associations to make a single 10-nm IF of 10-20 /lm in length. 
The precise arrangement of subunits in IFs has not yet been eluci­
dated, although recent chemical crosslinking studies and computer 
modeling suggest that the interactions involved in epidermal IF 
assembly may be similar to those illustrated in Fig lA [8,9]. This 
model entails a small-10 amino acid residue overlap between the 
amino terminal end of helix lA and the carboxy terminal end of 
helix 2B (denoted by the hatched bars). The rod is flanked by non­
helical head (amino) and tail (carboxy) segments that are variable in 
size and in sequence. Given their diversity and their location on the 
IF surface, heads and tails have been implicated in imparting spe­
cialized functions to IFs. 
Molecular mutagenesis studies have provided considerable in­
sights as to the sequences required for IF formation. When headless 
and tailless versions of human Kl4 were expressed by transient 
transfection in cultured keratinocytes, they integrated into the en­
dogenous network without perturbation. However, when trans­
fected cells expressed truncated human Kl4s missing a few amino 
acids from either the amino or carboxy end of the rod, they exhib­
ited a perturbed keratin network. These rod mutants behaved in a 
dominant negative fashion to disrupt the keratin cytoskeletal net­
work [10]. When K14 or KS mutants were expressed in bacteria, 
purified by biochemical methods, and then assayed by in vitro recon­
stitution of 10-nm filaments, it was discovered that the truncated 
rod mutants often interfered with filament elongation, generating 
shortened filaments [11]. When the head and tail domains were 
sequentially removed from this pair of keratins, only the head do­
main ofKS was essential for filament formation [12]. Studies con­
ducted on simple epithelial keratins (see, e.g., [13,14]) and other IF 
proteins ([1S] and references therein) were consistent with these 
observations. 
More recently, the roles of individual amino acids within the rod 
have been explored through point mutagenesis studies. Even subtle 
amino acid substitutions in the highly conserved ends of the rod can 
be deleterious to filament formation [lS-17]. In contrast, helix­
disrupting residues such as proline can often be tolerated within the 
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Figure 1. Model of keratin filament assembly and correlation be­
tween mutation location and disease severity in genetic disorders of 
keratin. A) Model of 10-nm filament. Model is adapted from those de­
scribed recently in papers dealing with chemical crosslinking of interme­
diate filament proteins [8,9]. Ten-nanometer filaments are composed of 
protofibrils, which in turn are composed of protofilaments . The width of a 
protofilament encompasses four polypeptide chains. Protolilaments have 
been visualized as linear arrays of tetramers, overlapping slightly at their 
ends, a feature postulated in a recent model by S teinert et at (9] (the region of 
overlap is depicted here by the hatched bars). Tetramers are composed of two 
coiled-coil heterodimers . Composed of a type I and a type II keratin, each 
hetcrodimer is aligned in antiparallel, half-staggered fashion to form a tetra­
mer. The orientation of the dimers in these arrays is indicated by arrows, with 
the amino end at the base and the carboxy end at the tip. The carboxy half of 
the L12 linker segment is denoted by the small black box in the arrow. B) 
Location ofEBS, PPK, and EH mutations relative to the secondary structure 
of the keratin polypeptides. Stick figures depict secondary structures of 
human type II and type I keratins [6]. Large boxes encompass the central rod 
domain, predicted to be largely a-helical. The a-helix is interrupted by three 
short non-helical linker regions, which subdivided the rod into four seg­
ments. Hatched boxes denote conserved ends of the rod, which are also regions 
involved in the putative overlap outlined in A. Bars denote non-helical head 
and rail domains, often variable in size and sequence. Arrowheads denote 
positions of mutations. In EBS (KS and K14 mutations) , D-M forms of the 
disease tend to be clustered in the highly conserved ends of the rod, K-forms 
tend to reside at locations elsewhere within the a-helical rod domains, and 
W-C forms are often in non-helical regions, either L12 or H1. PPK muta­
tions are denoted by the solid dots (K9 and Kl mutations), to distinguish them 
from those found in EH (Kl and KI0 mutations) . Asterisk for K5 mutation 
denotes rare homozygous autosomal dominant K173N mutation (see Ste­
phens et ai, 1994, legend to Table I). Asterisk for K14 mutation denotes rare 
recessive E144A mutation. Adapted from [6). 
central portion of the rod, without gross perturbations to filament 
structure [17]. Interestingly, prolines are naturally found in the 
linker regions. Their removal causes filament aggregation, suggest­
ing that the helix-perturbing units within the rod may perform in 
the proper spatial arrangement of filaments within a cell [17]. 
EPIDERMOLYSIS BULLOSA SIMPLEX: A FAMILY OF 
GENETIC DISORDERS OF BASAL KERATINS 
Epidermolysis bullosa simplex (EBS) is a group of rare genetic skin 
diseases affecting 1 : 50,000. EBS cases are usually autosomal domi­
nant, and clinical manifestations are usually present at birth. The 
diseases are typified by intraepidermal blistering due to cell degen­
eration within the basal layer [18]. Blistering is associated with 
mechanical stress, and these blisters tend to heal without scarring. In 
all EBS types, only basal cells exhibit signs of cell degeneration and 
cytolysis. Suprabasal layers are unperturbed, indicative of normal 
terminal differentiation. 
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EBS has been divided into three major types [19]. In Dowling. 
Meara ( D-M) and Koebner (K) EBS, blistering is generalized and 
pronounced [20]. Weber-Cockayne ( W-e) is milder, with blisten 
usually confined to palmar and plantar regions of the body [21].10 
addition, whereas keratin filaments in basal cells of milder EBS cast! 
often appear nearly normal or only mildly aggregated, those in bas� 
cells of D-M EBS have large clumps or aggregates of tonofilamena 
[20]. In some cases, aggregates are so amorphous that it is not del! 
whether keratins are in filamentous form. In K EBS and mildly 
severe D-M EBS, the filamentous nature of the keratins is evident 
EBS tonofilament clumps are recognized by antibodies against K5 
and K14 [22,23]. 
The electron microscopy studies of Dr. Ingrun Anton-Lamprecht 
provided the first insights that EBS might be a keratin disorder 
[20,21]. In ultrastructural studies of skin biopsies of D-M EBS pa· 
tients, she noted that tonofilament clumping was related to the stan 
of the pathogenetic process, suggesting that the disease might arill 
from structural defects in keratin as opposed to proteolytic abnor· 
malities. It was not until nearly ten years later that experiment� 
evidence for this hypothesis was obtained. Kitajima et at [24] demo 
onstrated that keratinocytes cultured from patients with EBS D·M 
have a perturbed keratin network, similar to that of keratinocytes 
transfected with mutant K14 genes [to]. Then, using a reverse ge· 
netic approach, our laboratory introduced a mutant human K14 
gene into the germline of transgenic mice [22,25]. We had previ· 
ously demonstrated that this truncated keratin, missing most of 
helix 2B of the rod, severely perturbed IF formation in keratino· 
cytes in culture [to] and assembly in vitro [t 1 J. In mice, the truncate� 
human keratin gene acted in a dominant-negative, i.e., autosorrul 
dominant fashion, causing nearly all of the phenotypic, morpho­
logic, and biochemical aberrancies of D-M EBS [22J. 
Subsequently, when we engineered transgenic mice expressing a 
mutant that only mildly perturbed keratin filament assembly, the 
mice displayed a phenotype more similar to W -C EBS [25]. Thus, 
different types of mutations in a single, namely K14, gene could 
give rise to mice with characteristics of different subtypes of EBS. 
Collectively, the transgenic mouse studies provided compelling ev· 
idence that structural defects in K 14 and K5 genes could generate an 
EBS phenotype, and that the degree to which a specific K14 or K5 
mutant perturbed 10-nm filament assembly correlated with the 
corresponding severity of the EBS phenotype. 
Recent studies using improved markers have shown that the ge­
netic defect of several K and W -C EBS families mapped to human 
chromosomes 17 or 12 [26-30]' at locations corresponding to the 
loci for type I and type II keratin gene clusters, respectively [31,32]. 
Unequivocal evidence that human EBS can arise from genetic de­
fects in K5 and K14 came from sequencing these ge):les isolated 
from EBS patients. Thus far, 11 different D-M EBS cas�s have been 
shown to contain point substitutions in either their K5 or K14 genes 
(Fig IB). In our first study of D-M EBS, we examined the K5 and 
K14 genes of two patients representing spontaneous cases of this 
disease [33]. We showed that both of these patients had single point 
mutations in K14, giving rise to a R125C mutation in one case and a 
R125H mutation in the other [33]' We have now found two more 
cases of the K14 R125C mutation and Stephens et al [34] have found 
four additional cases of the R125C and one additional case of the 
R125H mutation in unrelated patients with D-M EBS. In another 
case of D-M EBS, affected members had an E475G mutation in 
keratin 5 [35]. Recently, a D-M patient was found with a 30 amino 
acid deletion, removing a part of helix lA (A. Hovnanian, personal 
communication; Bracket in Fig IB). It is noteworthy that these 
D-M mutations are localized in the highly conserved rod ends ofKS 
and K14-regions previously demonstrated to be critical for IF 
network formation [17]. 
In contrast to the D-M cases, K EBS seems to have mutations that 
map within the a-helical rod, but outside the conserved rod ends 
[26,36-38]. The first K EBS case studied has affected family mem­
bers with a L384P mutation in helix 2B of the K14 rod [26]. An­
other case of K EBS revealed a L463P mutation in the helix 2B of 
K5 [36]. A single amino acid deletion, K14Llli375, has also been 
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reported [38]. Although these are the only proline mutations so far 
identified, it is notable that a genetically engineered proline within 
a few residues of these naturally occurring ones was not as disru�tive 
to IF formation as more subtle mutations within the rod ends L 17]. 
So far, the mildest cases ofEBS have mutations that map outside 
the a-helical segments of KS and K14 (Table I). We recently 
discovered that affected members of two W -C EBS families have 
defects that map to the keratin cluster on chromosome 12 and also 
have a G to T transversion leading to 1161S mutation in the head 
domain ofKS [29]. This mutation is within the portion of the KS 
head important for 10-nm filament assembly in vitro [12]. In four 
other cases of W -C EBS and one case of K EBS, mutations were 
found within the nonhelical linker separating helix lB from 2'A of 
K14 and K5 ([30,37,39]; Fig IB). Finally, in a rare recessive case of 
EBS, researchers discovered a homozygous 144 Glu -+ Ala muta­
tion near the end of a-helical segment lA of K1 4 [40]. 
The location of mutations in EBS relative to the clinical severity 
of the disease correlated remarkably well with what would be pre­
dicted on the basis of our previous random mutagenesis studies on 
K5 and K14 [10-12,17]. However, to demonstrate that the precise 
keratin mutations discovered in patients were truly responsible for 
the EBS phenotype and to verify the link between disease severity 
and the degree to which a mutant disrupted IF assembly, we geneti­
cally engineered four EBS mutations in the wild-type human K14 
or KS cDNAs [33,41]. Three D-MEBS mutations, K14R12SC/H 
and KSE47SG, caused collapse of the keratin network and punctate 
keratin aggregates at the cell periphery in a percentage of trans­
fected human epidermal cells [41]. This behavior was similar to that 
observed in a fraction of cells cultured from EBS patients with D-M 
EBS. In addition, bacterially produced D-M mutants assembled into 
only short filaments when combined with their wild-type counter­
parts in vitro [41]. These filaments resembled the shortened fila­
ments typically generated from D-M EBS patients' keratins [33]. 
Thus, these single point mutations were sufficient to cause the tono­
filament clumping and filament shortening that are hallmarks of 
the D-M type of EBS. In contrast� one of the K EBS mutations, 
K14L384P, exhibited significantly milder effects on both IF net­
work formation in vivo and IF assembly in vitro [41]. The KS 1161S 
and Ll-2 W-C mutations scored as even milder when subjected to 
these experimental tests [29,30]. Interestingly, these mutations ap­
peared to have a greater effect on lateral associations rather than on 
filament elongation. Collectively, our studies using EBS mutants 
are in good agreement with our random mutagenesis studies and 
underscore the existence of a correlation between i) the location of a 
mutation relative to the keratin polypeptide, ii) the degree to which 
such a mutation can perturb IF network formation and IF assembly, 
and iii) the clinical severity of the EBS disease. Figure IB (see also 
Table I) summarizes the location of the known mutations of EBS 
relative to keratin secondary structure. 
Figure 2 illustrates basal cell ultrastructure as compared with 
specific EBS mutations. Keratin clumping is the diagnostic feature 
of the D-M form of the disease [19]. and all of the patients that we 
have seen with the K14 R12SH/C mutations have displayed tono­
filament clumping at the ultrastructural level. In contrast. the de­
gree of filament aggregation is not a reliable measure of disease 
severity. A notable exception is the Koebner EBS patient with a K14 
A247D point substitution (Fig 2D,E; E. Hutton and E. Fuchs. 
unpublished). This patient exhibited severe cytolysis and blistering. 
but ultrastructurally keratin IF abnormalities were difficult to dis­
cern and. if anything. less rather than more filament aggregation 
was seen. Hence. for the milder cases ofEBS. ultrastructural abnor­
malities cannot always be used to predict regional location of muta­
tion. Nevertheless. to date, there has emerged a reasonably good 
correlation between disease severity and locations of mutations in 
three general regions. i.e .• a-helical end segments (D-M), a-helical 
rod segment (K). and non-helical segments (W -C), and if this trend 
holds up upon more comprehensive analyses. this information 
could be valuable in developing new and improved methods for 
diagnosis of the disease and for identification of the mutarion in an 
individual. 
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Figure 2. Gradient of ultrastructural severities in keratin architec­
ture amoug EBS types. Epidermal basal cells from (A) normal skin; (B) 
mild w-c EBS (KS-M327S); (e) severe W-C EBS (KS-I161S); (D) severe 
K EBS (K14-A247D); (B) higher magnification of D; (F and F') keratin 
(tono) filament clumps (KC) in severe D-M EBS (K14-R12SC); (G) lower 
magnification ofF'. Note lateral aggregation ofIFs in (C), ofren character­
istic of W-C and K EBS. The K EBS in (D-B) is an exception. where 
extensive cytolysis occurred in absence of keratin clumping or aggregation. 
but in presence of unusually short and thin filament bundles. The D-M EBS 
ultrastructure shown is typical. where clumps of keratin with no discernible 
filamentous structures are seen. For the K-EBS case shown. we did not detect 
any other amino acid change in the KS or K14 rod segments of this patient. 
but we cannot yet say that this mutation is functionally responsible for the 
disease (Hutton and Fuchs. unpublished). Bars, 1 p.m. N. nucleus. Arrow­
heads, keratin filament bundles; arrows, basal lamina; asterisks, vacuoles and/ 
or cell cytolysis. 
EPIDERMOLYTIC HYPERKERATOSIS: A GENETIC 
DISORDER OF SUPRABASAL KERATINS 
Epidermolytic hyperkeratosis (EH) is a rare form of ichthyosis [1]. 
Like EBS. it is an autosomal dominant disease with clinical manifes­
tations present at birth. The histopathology of EH is typified by 1) a 
normal. but hyperproliferative. basal epidermal layer; 2) tonofila­
ment clumping and perinuclear shells of tonofilament aggregates in 
suprabasal cells; 3) cell degeneration in suprabasal layers. beginning 
in the lower spinous layers and increasing during terminal differen­
tiation; and 4) a thickened granular layer and stratum corneum. Pal­
moplantar keratoderma has features that suggest it is a mild form of 
EH, and ichthyosis hystrix is likely to belong to this category of 
diseases as well. 
A clue to the genetic basis of EH stems from the similarity be­
tween the tonofilament clumping that occurs in suprabasal cells of 
EH skin and in basal cells ofEBS skin [42]. EH clumps label with 
antibodies specific for Kl and K10 [43.44]. Given the mirror image 
parallels between the morphologic and ultrastructural characteris­
tics of EBS and EH. coupled with the knowledge that. as epidermal 
cells commit to terminally differentiate. they switch to expressing 
Kl and K10. we predicted from our first transgenic mouse studies 
that EH would be a genetic disorder of Kl and K10 [22]. 
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Indeed transgenic mice expressing a truncated human KlO gene 
exhibited pathobiologic and biochemical characteristics of human 
EH [45]. In separate studies, linkages of affected members ofEH and 
palmoplantar keratoderma ( PPK) to the keratin gene clusters on 
chromosome 12 and 17 were reported, further strengthening the 
notion that these suprabasal diseases are disorders of keratin [46-
52]. Conclusive evidence came from direct sequencing of the Kl 
and KI0 genes isolated from patient DNAs. Initially, in three inde­
pendent studies, point mutations were discovered in the KI0 or Kl 
genes of distinct incidences of human EH [44,53,54]. A number of 
additional point substitutions have now been described [48-60]. 
The story emerging from EH is remarkably similar to that of 
EBS. In two distinct EH families [44], several additional cases ofEH 
[54,55,59,60], and several epidermolytic palmoplantar keratoderma 
(EP PK) families [49-51], arginine to cysteine and histidine point 
mutations in KlO (EH) and K9 (EPPK), were even in the exact same 
arginine residue that, when mutated in K14, gave rise to EBS 
[33,34]. This represents the first observation of a mutation in a 
highly conserved residue of three differentially expressed genes giv­
ing rise to three distinct genetic diseases. In addition, several severe 
incidences of EH have mutations in the highly conserved end do­
mains of the Kl or KI0 rod segment [4,52-60]' and affected mem­
bers of a mild case ofEH have a mutation in the Kl head [53], only a 
few amino acid residues amino to the equivalent residue mutated in 
the K5 gene of the two W-C families described above [29]. Al­
though functional studies for EH and/or Kl and KlO mutations 
[44,53,56] are not as extensive as those conducted on EBS mutations 
and/or K5 and K14,judging from parallels with EBS, there would 
seem to be a solid correlation between location of the mutation and 
the severity of the EH disease. 
Figure lB and Table I indicate the location of the EH, EBS, and 
PPK mutations thus far reported. All D-M EBS patients and all 
severe cases of EH thus far analyzed have mutations either in the 
amino end or the carboxy end of the keratin rod domain [33-
35,44-60]. The ends of the rod are highly evolutionarily con­
served, and have been shown to be critical for the packing of IF 
subunits into 10-nm filaments [10-15]. Recent chemical cross­
linking studies coupled with computer modeling have led to the 
hypothesis that staggered keratin tetramers link end-to-end in a 
slightly overlapping fashion, such that the first -10 residues of the 
lA helices from one heterodimer overlap with the last -10 residues 
of the 2B helices from another (Figure lA, hatched bars denote 
potential overlap; see also [8,9)). End-to-end interactions between 
the rod ends would be predicted given the location of D-M EBS and 
EH mutations and the effects that these mutations have on produc­
ing shortened keratin filaments when combined with their wild­
type partners in vitro [33,41]. In contrast, mutations in the L1-2 
region seem to have a much greater effect on lateral associations 
than on end-to-end associations [30]. The Ll-2 mutations seem to 
be clustered in the carboxy end of the L1-2 linker and, given the 
limitations of current chemical cross-linking data, it is possible that 
this end of the linker is in direct proximity to the putative helix 
lA/helix 2B overlap (Fig lA). If so, these mutations could affect 
the staggered alignment of dimers, which in turn could translate 
into perturbations on higher-ordered lateral associations. Further 
experiments will be necessary to determine the extent to which this 
notion is correct. 
In contrast to the severe cases ofEBS, Koebner mutations, includ­
ing two proline mutations [26,36], a single amino acid deletion 
K14lill375 [38], and a K14A247D mutation [E. Hutton and E. 
Fuchs, unpublished], reside in less conserved a-helical rod seg­
ments. A priori, a proline in the coiled-coil segment of the rod might 
be expected to dramatically perturb IF structure. In fact, however, 
pro lines can be accommodated at a number of central positions 
within the K14 ( and presumably K5) rod, with only a rather subtle 
effect on IF assembly [17]. Even more surprising are the mutations 
in the type II head domains ofKl and K5 in milder cases ofEH and 
EBS, respectively [29,53]. Several biochemical studies have under­
scored the importance of the head domain of the type II keratins in 
IF structure [12,13,61], although most molecular models for IF 
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Table I. Summary of Mutations Found in Patients with 
EBS, EH, and PPK 
Gene Disease Mutation Domain RefereoCl 
K14 D-MEBS R125H (2) 1A [33,34,631 K14 D-MEBS R125C (7) 1A [33,34,63 K14 KEBS L384P 2B [26] 
K14 KEBS M272R L12 [37] 
K14 KEBS A247D 1B 
K14 KEBS AE375 2B [38] 
K14 W-CEBS V270M L12 [39] 
K14 EBS-rec E144A lA [40] 
K5 D-MEBS E475G 2B [35] 
KS D-MEBS t.30 aa HI/1A b 
K5 KEBS L463P 2B [36] 
K5 EBS-hom K173N lA 
K5 W-CEBS 1161S (2) Hl [29] 
K5 W-CEBS M327T L12 [30] 
K5 W-CEBS N329K L12 [30] 
K5 W-CEBS R331C L12 [39] 
KI0 EH R156H (5) 1A [44,54,571 
K10 EH R156C (2) lA [56,57] 
K10 EH R156P lA [59] 
KI0 EH R156S 1A [59] 
K10 EH M150R lA [56] 
KIO EH N154H lA [57] 
K10 EH L1l61S lA [54] 
KI0 EH Y 160D lA [57] 
K10 EH Y160N 1A [51] 
K10 EH L442Q 2B [57] 
K10 EH mild K439E 2B [56] 
Kl EH S185P lA [59] 
Kl EH N187P lA [59] 
Kl EH N187S 1A [58] 
Kl EH S19 2P lA [58] 
Kl EH Y481C 2B [56] 
Kl EH E489 Q 2B [54] 
K1 EH-mild L160P Hl [53] 
K1 EH-mild V154G H1 [58] 
K1 PPK-mild K731 V1 [52] 
K9 EPPK N160Y lA [51] 
K9 EPPK N160K 1A [50] 
K9 EPPK Rll62Q 1A [50] 
K9 EPPK Rll62W 1A [50] 
, E. Hutton and E. Fuchs, unpublished. 
• Hovnanian A, et 01: A mutation in! the splice donor site of intron 1 of the keratin 5 
gene in the Dowling-Meara form of epidermolysis bullosa simplex (abstr). ] InvtJI 
Dermatol103:610,1994. 
, Stephens K, et 01: An epidermolysis bullosa simplex patient with a keratin 5 homo-
zygous defect (abstr).] Invest DermatoI102:609, 1994. 
structure have not yet taken into account the non-helical domains of 
IF proteins. Although future studies will be necessary to appreciate 
fully the structural significance of certain residues within the epi­
dermal keratins, it appears tha.t even subtle perturbations to IF struc­
ture in vitro ca.n cause EBS or EH in vivo. 
Given that the mutations found in EBS and EH patients are in 
regions identified as being critical residues for lO-nm filament as­
sembly, it seems likely that as additional mutations are mapped this 
pattern will continue. Thus, we might expect to find additional 
D-M EBS and severe EH mutations in conserved residues of the rod 
ends, and less severe EBS and EH mutations in residues that are not 
as crucial for IF assembly. This said, an added element to consider is 
exemplified by the high frequency of mutations in the helix lA 
arginine of K14 (EBS) and KlO (EH). This residue is arginine or 
lysine in 50 of 51 published n; protein sequences [33], and therefore 
is highly conserved. It is relevant that the mutated arginine is en­
coded by (CGe). Mutation to a cysteine (TGe) or a histidine 
(CAe) both involve a C --> T transition at a CpG sequence on either 
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the coding strand (Arg -+ Cys) or the noncoding strand (Arg -+ 
His). It is well known that eukaryotic 5-methyl cytosine methylases 
can act at CpG dinucleotide sequences and, if a methylated cytosine 
is deaminated, this generates a C -+ T transition. In fact, more than 
30% of point mutations in all human genetic diseases are C -+ T 
transitions at CpG dinucleotides [62,63]' This said, there are more 
than 200 CpG dinucleotide sequences in the four epidermal keratin 
genes, and several of these are localized within the conserved ends of 
the rods. Although our understanding of IF structure has not 
reached a level where we can appreciate why these mutations have 
not yet appeared in severe EBS or EH cases, we have engineered and 
tested these other mutations in the laboratory and they do. not 
grossly perturb keratin filament assembly as does the EBS/EH hot 
spot arginine [41]. As additional studies are conducted, the selective 
importance of this arginine residue on keratin filament structure 
should become more apparent. 
In contrast to the K14 R125C/H mutations, the K5 1161S muta­
tion is a G to T transversion and cannot be generated by cytosine 
methylation and deamination. Yet, this mutation was seen in 20% 
ofW -C EBS cases that we examined. At present, there is no known 
mechanism for generating this type of mutation as a genetic hot spot 
for mutagenesis. If there is no underlying genetic propensity for this 
residue to be more frequently mutated than others, the 1161 S muta­
tion may be one of only a few ways of generating the W -C pheno­
type. Another way appears to be mutagenesis of the linker separat­
ing helices 1B and 2A of keratin 5 [30,39]. 
It is intriguing that the K5 1161S mutation in the two W-CEBS 
families generates a gotential phosphorylation site, Ser-Gln-Arg, 
for protein kinase C l29]. Although the possible significance of this 
observation remains to be determined, it is notable that cdc kinase­
mediate phosphorylation of serines in the head regions of two other 
IF proteins, lamin A (type V) and vimentin ( type III), are responsible 
for destabilizing these IF networks during mitosis (see, for example, 
[15]). Moreover, phosphorylation of IFs by PKC can trigger such 
diverse responses as disassembly of in vitro formed polymers of vi­
mentin and nuclear import of lamin B in vivo (see [29]). Taken 
together, phosphorylation might playa role in mediating the dele­
terious effects of the Ile -+ Ser mutation on IF network formation in 
W -C EBS basal cells. This could also explain why the effects of this 
mutation on in vitro assembly of IFs were not appreciable. 
In addition to enabling predictions as to the possible locations of 
future EBS, EH, and EPPK mutations, the cell biology has provided 
an understanding of many previously unexplained aspects of these 
diseases. The autosomal dominance arises because mutant keratins 
are able to recognize their obligatory heterotypic, wild-type 
partners, and thus act in a dominant-negative fashion to perturb 
JrcmiD network formation. The .m:mifestariOD of the diseases in 
either the basal (EBS) or suprabasal (EH and EPPK) layers of the 
� • do< to tire � "1'''''''"0 ot tire K5(Kt4 md 
'.:JK .. ... 10/K9 keratin gene groups. In severe cases of EBS, clinical 
. • estations can occur in other stratified squamous epithelia, in­
. 
., g nail, oral mucosa, cornea, and esophagus, because these cells 
lifo express K5 and K14, albeit to a lesser extent in most tissues than 
tfpidenDis. In contrast, gross perturbations in these stratified squa­
�� epithelia occur rarely if at all in EH patients, consistent with 
�more restricted pattern ofKl/K10 expression. Finally, the re­
pCIliGted." expression of K9 in palmar and plantar skin give EPPK 
highly restricted clinical manifestations. 
-. A major question is why are EBS, EH, and EPPK cells prone to 
_lysis? A number of findings point to the hypothesis that without 
II proper keratin network, cells become fragile and prone to break­
�upon mechanical stress. Thus, in the initial phases of blistering 
IfBBS, cells often rupture in a defined zone, beneath the nucleus 
Iild above the hemidesmosomes [21,25]. This is the longest portion 
o£the columnar basal cell, and the zone expected to be most fragile 
IV a consequence ofEBS or EH keratin mutations that often seem to 
compromise filament elongation. Thus, keratin filaments function 
,in part by imparting mechanical integrity to an epidermal cell. 
A knowledge of keratin expression can also help us to understand 
why, in EBS, blisters generally heal without scarring. In mice, basal 
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cells flatten during wound healing, they reduce K5 and K14 synthe­
sis, and cytolysis appears to cease [25]. In addition, when EBS kerati­
nocytes flatten on a culture dish, they are no longer as susceptible to 
lysis as when in the context of the tissue [25,31]. Collectively, these 
results suggest that 1) lysis is a mechanical trauma-dependent phe­
nomenon, one likely to occur from a direct compromise to mechan­
ical integrity, and 2) mechanical stress may be greater when cells are 
cuboidal or columnar than when cells are flattened. If enzymatic 
changes occur in EBS, these aberrations are likely to be secondary. 
In the four years since genetic data on EBS, EH, and EPPK have 
begun to accumulate, it has become apparent that a majority of 
incidences of these disorders involve mutations in epidermal keratin 
genes. In addition, a trend has emerged whereby the severe cases 
often have a point mutation in the conserved rod ends of one of their 
basal (EBS) or suprabasal (EH and EPPK) keratins. If this pattern 
continues to hold, then it may be possible to develop DNA screen­
ing methods for prenatal diagnoses of these diseases. The develop­
ment of genomic tools would enable diagnoses from chorionic 
villus samples, rather than by electron microscopy of skin biopsies 
obtained intrauterinely via fetoscopy under ultrasonic control (for 
review, see [64]). In addition, an antibody is already available that 
can distinguish mutant from wild-type sequences at the carboxy 
terminus of the IF rod end [35]. It may also be possible to develop 
antibodies specific for the amino end of the IF rod domain. If so, it 
may be possible to use immunologic tools to identify the region of a 
specific keratin that is defective in an EBS, EH, or EPPK patient. 
This could then facilitate genetic screening analysis of potential 
offspring, enabling prospects for future genetic counseling of the 
most severe incidences of these diseases. 
what are the prospects for improving therapeutic methods for 
EBS, EH, and EPPK? At present, it is too early to say. Certainly, the 
possibilities for cures for autosomal dominant, structural gene de­
fects are limited even within the realms of modem day medicine. 
However, given that keratinocytes can be cultured from a skin 
biopsy of an EBS, EH, or EPPK patient, it may be possible to develop 
methods to remove genetically the defective gene in cultured cells, 
and then graft these repaired cells back onto the patient. Procedures 
for culturing keratinocytes and grafting them onto the same patient 
are currently being used routinely in bum operations [64], and thus a 
portion of the necessary technology is already in place. Because 
there should be a tremendous selective advantage for healthy kerati­
nocytes over cytolysis-prone keratinocytes, at least for EBS where 
the disease is manifested in the mitotically active layer, it is possible 
that genetically repaired keratinocytes from a patient with an epi­
dermolytic disease could populate a region of skin beyond the extent 
of a graft. If so, severe cases of these diseases might be amenable to 
gene therapy. Fumre sDJdjes will be 11CCI!SS:ll)' to fv.rtbcr expJore the 
feasibility of such an approach. 
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